Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC

Summary

This is a single-arm, phase 2 study to investigate the efficacy and safety of sunvozertinib as neoadjuvant and adjuvant treatment for stage II-IIIB non-small-cell lung cancer patients with EGFR exon20 insertion mutation.

Timeline

Start

2025-02-18

Primary completion

2026-12

Completion

2029-06

Drugs

Indications